Experience | Leaflets | Support | Patient+ | Guidelines | Weblinks | Videos | News | Products | Other
Other options: 
This is a PatientPlus article. PatientPlus articles are written for doctors and so the language can be technical. However, some people find that they add depth to the articles found in the other sections of this website which are written for non-medical people.
Cancer Antigen 125 (CA-125)
Post your experienceThis is a surface antigen on a high-molecular weight glycoprotein recognised by a monoclonal antibody (produced using an ovarian cancer cell line).1 It is most useful as a marker for non-mucinous ovarian epithelial cancer2, and indeed is present in up to 80% of cases of advanced ovarian cancer - but is often negative earlier in the disease.3
|
Conditions which may have elevated CA-125
Malignant Disease
Non malignant conditions
|
CA-125 kU/L <30 (may vary between laboratories).
Monitoring known patients with ovarian cancer for relapse
Three studies have looked at the correlation of CA-125 in patients treated for ovarian cancer who subsequently underwent a second staging operation to look for any persisting disease.7,8,9 Combining the results1, the CA-125 has a sensitivity of 55% and a specificity of 96%, giving a positive predictive value of around 96% and a negative predictive value of 53%. Thus in patients with known ovarian cancer a rising CA-125 is a good indicator of residual disease but a normal result will be a false negative about half the time in this group (not a good indicator of small volume disease).
Investigation of female patients with a pelvic mass
CA-125 can be used in the assessment of patients presenting with a pelvic mass. An elevated result has a sensitivity of 72% and specificity of 78% for ovarian cancer (positive predictive value of 72% and a negative predictive value of 78%).10 If combined ultrasound results and menopausal status, a risk of malignancy index (RMI) can be calculated. Using a cut-off level of CA-125=200 to indicate malignancy, the RMI gave a sensitivity of 90%, specificity of 89%, positive predictive value of 96%, and negative predictive value of 78% in this group.11
Screening for Ovarian Cancer
The relatively low prevalence of ovarian cancer means that the positive predictive value of CA-125 as a screening test is extremely low.12 CA-125 is being evaluated as a screening tool for patients at high risk of ovarian cancer, in combination with other tests. The UK Familial Ovarian Cancer Screening Study (UKFOCSS) is recruiting women with strong family histories or mutations in BRCA1 or BRCA2, to be screened with trans-vaginal ultrasound scan of the ovaries and CA-125 three times a year.13 A second study, the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) study has finished recruiting, and compares annual CA125 screening with transvaginal ultrasound against no screening or just annual vaginal ultrasound.14,15
Document references
- William M. Rich, M.D. CA-125 www.gynoncology.com
- Kabawat SE, Bast RC, Welch WR, et al; Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Pathol. 1983 Jan;79(1):98-104. [abstract]
- Jacobs I, Bast RC Jr; The CA 125 tumour-associated antigen: a review of the literature. Hum Reprod. 1989 Jan;4(1):1-12. [abstract]
- Epithelial Ovarian Cancer, SIGN Guideline No 75 (October 2003)
- Moran-Mendoza A, Alvarado-Luna G, Calderillo-Ruiz G, et al; Elevated CA125 level associated with Meigs' syndrome: case report and review of the literature.; Int J Gynecol Cancer. 2006 Jan-Feb;16 Suppl 1:315-8. [abstract]
- Lacey JV Jr, Greene MH, Buys SS, et al; Ovarian cancer screening in women with a family history of breast or ovarian cancer. Obstet Gynecol. 2006 Nov;108(5):1176-84. [abstract]
- Patsner B, Orr JW Jr, Mann WJ Jr, et al; Does serum CA-125 level prior to second-look laparotomy for invasive ovarian adenocarcinoma predict size of residual disease? Gynecol Oncol. 1990 Sep;38(3):373-6. [abstract]
- Petru E, Sevin BU, Averette HE, et al; Comparison of three tumor markers--CA-125, lipid-associated sialic acid (LSA), and NB/70K--in monitoring ovarian cancer. Gynecol Oncol. 1990 Aug;38(2):181-6. [abstract]
- Rubin SC, Hoskins WJ, Hakes TB, et al; Serum CA 125 levels and surgical findings in patients undergoing secondary operations for epithelial ovarian cancer. Am J Obstet Gynecol. 1989 Mar;160(3):667-71. [abstract]
- Patsner B, Mann WJ; The value of preoperative serum CA 125 levels in patients with a pelvic mass. Am J Obstet Gynecol. 1988 Oct;159(4):873-6. [abstract]
- Obeidat BR, Amarin ZO, Latimer JA, et al; Risk of malignancy index in the preoperative evaluation of pelvic masses. Int J Gynaecol Obstet. 2004 Jun;85(3):255-8. [abstract]
- Screening for ovarian cancer: a systematic review. Health Technology Assessment 1998; Vol. 2: No. 2 (Executive summary)
- Breakthrough - UK Familial Ovarian Cancer Screening Study
- UK Collaborative Trial of Ovarian Cancer Screening
- Menon U, Gentry-Maharaj A, Hallett R, et al; Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol. 2009 Mar 10. [abstract]
Document ID: 3179
Document Version: 23
Document Reference: bgp25953
Last Updated: 21 Apr 2009
Planned Review: 21 Apr 2011
The authors and editors of this article are employed to create accurate and up to date content reflecting reliable research evidence, guidance and best clinical practice. They are free from any commercial conflicts of interest. Find out more about updating.
Patient UK Hearing Impairment Survey
Patient UK are grateful to the 550 people who took part in this survey.
To see the results click here.
If you'd like to leave your feedback, please go to our interactive forum.
Experience | Leaflets | Support | Patient+ | Guidelines | Weblinks | Videos | News | Products | Other
Other options:
Related pages in Patient UK
Your Experience (^ top of page)
Please add your experience about this condition / medicineHealth Topic information leaflets related to this topic (^ top of page)
Cancer of the OvarySupport Groups related to this topic (^ top of page)
Ovacome Ovarian Cancer Action Target Ovarian Cancer Women's Health ConcernPatientPlus articles related to this topic (^ top of page)
Meigs' Syndrome Ovarian Carcinoma Tumour MarkersUK guidelines related to this topic (^ top of page)
Guidelines on Ovarian CancerLinks to other selected websites related to this topic (^ top of page)
Cancer of the OvaryVideos related to this topic (^ top of page)
Links to online videos on Ovarian CancerPatient UK Newspaper (^ top of page)
Recent related news items
Biggest DNA cancer breakthrough in 20 years Speedier tests for cancer planned Doctor's hunch saved my life Spotting ovarian cancer Ovarian cancer 'is being missed'All news by related topic
Ovarian Cancer newsRelated Products (^ top of page)
Medical equipment
Books
Other - Useful resources (^ top of page)
Pictures, diagrams, photos, images, etc.Evidence based medicine
Online textbooks and journals
UK Guidelines
Online Videos
Medline
Other good health sites
Want to search some more? Use the Google Search box below to search our site.
Disclaimer: Patient UK has no control over the content of any external links above. Inclusion does not imply endorsement by Patient UK.
Want to advertise on this site? Find out how >>
Here you can follow a link to view existing patient experiences on this subject, or to add your own
This will offer you the usual PDF options i.e. document navigation, search, zoom and formatted print
Note: this is the best way to print the document
Note: this will open in a new window
Note: this will open in a new window
Here you can follow a link to view existing patient experiences on this subject, or to add your own
This will offer you the usual PDF options i.e. document navigation, search, zoom and formatted print
Note: this is the best way to print the document
Note: this will open in a new window
Note: this will open in a new window